Comera Investor Presentation Deck

Comera Life Sciences Investment Highlights Near-Term Milestones Lower-Risk Development ● Capital Efficient Comera LIFE SCIENCES Partnerships yield near-term licensing fees; IND filing milestones within ~2 years • Focus on reformulation of existing drugs Multiple Shots on • SQore TM technology can be applied across multiple partnership and pipeline programs Goal Business model characterized by low operating cost and development spend

View entire presentation